These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1193 related articles for article (PubMed ID: 29045212)

  • 21. Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials.
    Wallenstein GV; Kanik KS; Wilkinson B; Cohen S; Cutolo M; Fleischmann RM; Genovese MC; Gomez Reino J; Gruben D; Kremer J; Krishnaswami S; Lee EB; Pascual-Ramos V; Strand V; Zwillich SH
    Clin Exp Rheumatol; 2016; 34(3):430-42. PubMed ID: 27156561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.
    Bird P; Bensen W; El-Zorkany B; Kaine J; Manapat-Reyes BH; Pascual-Ramos V; Witcombe D; Soma K; Zhang R; Thirunavukkarasu K
    J Clin Rheumatol; 2019 Apr; 25(3):115-126. PubMed ID: 29794874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo.
    Gladman DD; Coates LC; Wu J; Fallon L; Bacci ED; Cappelleri JC; Bushmakin AG; Helliwell PS
    Arthritis Res Ther; 2022 Feb; 24(1):40. PubMed ID: 35139908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
    Kivitz AJ; FitzGerald O; Nash P; Pang S; Azevedo VF; Wang C; Takiya L
    Clin Rheumatol; 2022 Feb; 41(2):499-511. PubMed ID: 34510295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
    Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
    Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tofacitinib: A Review in Psoriatic Arthritis.
    Paik J; Deeks ED
    Drugs; 2019 Apr; 79(6):655-663. PubMed ID: 30895473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
    Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Chen L; Kudlacz E; Wu J; Cappelleri JC; Hendrikx T; Hsu MA
    RMD Open; 2019; 5(1):e000808. PubMed ID: 30713722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.
    McInnes IB; Kim HY; Lee SH; Mandel D; Song YW; Connell CA; Luo Z; Brosnan MJ; Zuckerman A; Zwillich SH; Bradley JD
    Ann Rheum Dis; 2014 Jan; 73(1):124-31. PubMed ID: 23482473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.
    Strand V; van Vollenhoven RF; Lee EB; Fleischmann R; Zwillich SH; Gruben D; Koncz T; Wilkinson B; Wallenstein G
    Rheumatology (Oxford); 2016 Jun; 55(6):1031-41. PubMed ID: 26929445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study.
    Leng X; Lin W; Liu S; Kanik K; Wang C; Wan W; Jiang Z; Liu Y; Liu S; Zhang Z; Zhang Z; Xu J; Tan W; Hu J; Li J; Liu J; Gunay LM; Dina O; Kinch C; Zeng X
    RMD Open; 2023 Jan; 9(1):. PubMed ID: 36720560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan.
    Chen DY; Hsu PN; Tang CH; Claxton L; Valluri S; Gerber RA
    J Med Econ; 2019 Aug; 22(8):777-787. PubMed ID: 30982378
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
    Cohen SB; Koenig A; Wang L; Kwok K; Mebus CA; Riese R; Fleischmann R
    Clin Exp Rheumatol; 2016; 34(1):32-6. PubMed ID: 26575982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
    Sandborn WJ; Ghosh S; Panes J; Vranic I; Su C; Rousell S; Niezychowski W;
    N Engl J Med; 2012 Aug; 367(7):616-24. PubMed ID: 22894574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
    Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
    Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.
    Tanaka Y; Takeuchi T; Yamanaka H; Nakamura H; Toyoizumi S; Zwillich S
    Mod Rheumatol; 2015 Jul; 25(4):514-21. PubMed ID: 25496464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.
    Lomonte ABV; Radominski SC; Marcolino FMD; Brenol CV; Zerbini CAF; García EG; Akylbekova EL; Rojo R; de Leon DP
    Medicine (Baltimore); 2018 Aug; 97(31):e11609. PubMed ID: 30075534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.
    Curtis JR; Schulze-Koops H; Takiya L; Mebus CA; Terry KK; Biswas P; Jones TV
    Clin Exp Rheumatol; 2017; 35(3):390-400. PubMed ID: 28079500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.
    van der Heijde D; Tanaka Y; Fleischmann R; Keystone E; Kremer J; Zerbini C; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Wyman BT; Gruben D; Benda B; Wallenstein G; Krishnaswami S; Zwillich SH; Bradley JD; Connell CA;
    Arthritis Rheum; 2013 Mar; 65(3):559-70. PubMed ID: 23348607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
    Berekmeri A; Mahmood F; Wittmann M; Helliwell P
    Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.